A recently published study by Sparano et al. attempted to address this question by performing a secondary analysis of data from the TAILORx cohort, which included 1,389 women with hormone receptor–positive, HER2‐negative, node‐negative BC, and RS of ≥26.23 This evidence concerns the gene ERBB2 and breast cancer.